Navigation Links
Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
Date:12/7/2009

NEW ORLEANS and SUNNYVALE, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced interim data from a Phase I study of their novel orally administered Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL). These data are being presented at the American Society of Hematology (ASH) 51st Annual Meeting taking place this week in New Orleans, LA.

The multi-center dose escalation Phase I study is being conducted in collaboration with investigators at leading lymphoma centers including Stanford University, MD Anderson Cancer Center, the University of Chicago, the University of Vermont, and US Oncology group. The trial was designed to explore up to 6 dose levels with a minimum of 4 evaluable patients per cohort. Each cycle of treatment consists of 28 consecutive days of dosing followed by 7 days of rest. Safety is evaluated at the end of the first cycle and efficacy at the end of the second. At least one full cycle of treatment has been completed for each patient in the first 3 cohorts. Data from the second cohort demonstrated that PCI-32765 fully occupied the active site of the target enzyme Btk in peripheral blood cells with minimal variability, fully inhibited surrogate biomarkers for up to 24 hours, and was well tolerated by patients.

In the first 2 dose cohorts, 16 heavily pretreated and progressing lymphoma patients with a variety of B-cell malignancies were evaluated. In the first dose cohort, 7 patients were treated with PCI-32765 resulting in 2 partial responses (e.g. a 50% decrease in sum of the product of the diameters of up to 6 largest dominant masses; no increase in size of other nodes per the Revised Response Criteria for Malignant Lymphoma Bruce D. Cheson J Clin
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
2. Patriot Scientific Corporation Announces New Director
3. Lilly Announces the First 300-unit Vial of Insulin
4. Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S.
5. The Countrys Largest Cooking Magazine Announces The Comfort Food Diet Cookbook
6. BridgeGate International Announces New Integration and Interoperability Training Program
7. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
8. Distributor Announces New Applications for Wind Turbines
9. FRC Announces Campaign to Call Every Louisiana Household, Urging Opposition to Health Care Takeover
10. NeoGenomics Announces Executive Appointments
11. Hill-Rom Announces First Quarter 2010 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by JAMA Internal ... outnumber merely overweight Americans, Samir Becic emphatically declared a war on obesity in the ... now," Becic said. "We must understand the magnitude of this discovery. For that reason, ...
(Date:7/2/2015)... ... ... 2012, Patrick Achebe realized that the gift of poetry was fully in him, as beautiful ... poem, and three years later he was publishing an entire book of poetry. He knew ... "I have always believed that the best way to lift yourself up, is in the ...
(Date:7/2/2015)... Silver Spring, Md. (PRWEB) , ... July 02, 2015 , ... ... mile mark in his solo cross-country walk to raise awareness and money for the ... ago and expects to arrive at PHA’s headquarters near Washington, D.C. by mid-September. He ...
(Date:7/2/2015)... ... July 02, 2015 , ... Healthpointe ... to the orthopedic and spine surgery team at their Anaheim clinic. Dr. Krishnareddy ... tendonitis. Along with the spine and spine surgery, Dr. Krishnareddy also specializes in ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... solutions and management consulting services to the federal government, has announced they are ... Indefinite-Quantity (IDIQ), Business Management Office Support Services (BMOSS) contract not to exceed $250 ...
Breaking Medicine News(10 mins):Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2
... HIV positive people in Tamil Nadu and their support ... to draw attention of the UN towards non-implementation// of ... (UNGASS) to address the problem of HIV/AIDS. ... that UNGASS in 2001 had set goals like offering ...
... several years inflicting ‘tremendous damage’ to bird population, domestic ... of its turning into human pandemic affecting millions, the ... new assessment, the Food and Agriculture Organization upped its ... to USD 308 million over the next three years, ...
... carried a recent article on the benefits of ... ties, //suggesting that discussing others negative attitudes might ... friendship. ,Research shows that sharing negative ... promotes closeness and friendship. In their study, the ...
... As medical technology continues to advance fertility procedures such ... very common practice. // But a study published in ... that, even after thorough screenings of sperm donors, genetic ... ,Laurence Boxer, MD, and colleagues from the University ...
... Following completion of an exclusive Distribution Agreement with ... LTP's satiety ,ingredient Olibra(R)//, as a single dose ... has successfully ,launched its Slim 10/10 product into ... successful ever product launch into the French market, ...
... A paper was presented in the 21st Annual Meeting ... City. This revealed the link between the female sexual ... study it is said that mostly women with increased ... dysfunction is defined as persistent or recurring decrease in ...
Cached Medicine News:Health News:Link Established Between FSD and High Blood Pressure 2
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic Center ... leading provider for non-invasive aesthetics in Lakeway, ... removal treatments with the Astanza Duality laser. The medical ... being through various medical and laser procedures. Their addition ... ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... Numotion,s Board of Directors and Mike ... Feitel has joined the Company as Chief Financial ... successful 18 year career at GE serving in executive ... productivity to result in significant industry leading growth and ... Officer for GE Healthcare Global Services, a $5B P&L ...
(Date:7/2/2015)... , July 2, 2015   Decision ... European retinal specialists identify less frequent dosing as ... (DME), due to the burden on both patients ... endothelial growth factor (VEGF) injections, which are the ... Partners, abicipar pegol, which is in development for ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3
... KING OF PRUSSIA, Pa. , July 22 ...  Lost to follow up (L2FU) rates in clinical research trials ... drop from a clinical trial and ,go missing, can impart ... and obtain final closure data, or bring them back into ...
... Inc. (Nasdaq: ANDS ) announced today that it will report second quarter ... financial markets open. , , , ... a conference call and webcast on Thursday, July 29, 2010 at ... financial results and to provide an update on the ANA598 development program.  A ...
Cached Medicine Technology:Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study 2Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results 2
... Built on the market leading optical performance ... has been optimized for even better views ... system, including a new XHL Xenon Halogen ... cornea and clear, high resolution images of ...
... 2.2 Fr Sur-Catch NT stone retrieval basket raises ... Its unique paired wire design and multi-sizing ... the needs of each patient and procedure. ... for use with the DURTM-8 Elite Ureteroscope and ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
Medicine Products: